|Articles|August 14, 2021

CDC Booster Dose Recommendation Follows FDA EUA

The Centers for Disease Control and Prevention (CDC) endorses the additional COVID-19 vaccine shot in immunocompromised people.

The CDC’s Advisory Committee on Immunization Practices (ACIP) met yesterday to discuss whether to recommend the addition of a booster dose of the mRNA COVID-19 vaccines for people who are immunocompromised.

The CDC’s committee voted 11-0 in favor of recommending a third booster dose of the vaccines.

This endorsement came 1 day after the Food and Drug Administration’s (FDA) decision to expand the Emergency Use Authorization (EUA) for the addition of a singular booster dose of the mRNA vaccines in that same patient population.

CDC Director Rochelle Walensky, MD, MPH, signed the ACIP’s recommendation late yesterday. 

“This official CDC recommendation—which follows FDA’s decision to amend the emergency use authorizations of the vaccines—is an important step in ensuring everyone, including those most vulnerable to COVID-19, can get as much protection as possible from COVID-19 vaccination,” Walensky said in a statement.

In her statement, she said that while immunocompromised people in the United States only make up about 3% of the population, they are more vulnerable than the rest of the population as new data is showing that people with immunocompromised systems are not mounting the same immunity and are at risk of serious, prolonged illness.

Two other factors including breakthrough infections and transmission to household members were also referenced in the decision.

"Fully vaccinated immunocompromised people have accounted for a large proportion of hospitalized breakthrough cases (40-44%),” the CDC statement read. “Immunocompromised people who are infected with SARS CoV-2 are also more likely to transmit the virus to household contacts.”

The CDC said this new recommendation includes a number of people with various conditions including recipients of organ or stem cell transplants, people with advanced or untreated HIV infection, active recipients of treatment for cancer, people who are taking some medications that weaken the immune system, and some others. To learn more about the list of people within this category, check out the list the CDC developed.

“At a time when the Delta variant is surging, an additional vaccine dose for some people with weakened immune systems could help prevent serious and possibly life-threatening COVID-19 cases within this population,” Walensky said.


Related to this article

Measles Update: October 30, 2026
The latest CDC numbers show a 5.8% increase in measles cases from week-to-week, bringing the 2026 US total to more than double the amount seen in all of 2025 with 2 months left in the year.
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
FAQ: Shamonda Virus
As France confirms the first documented human Shamonda virus infection, a fatal encephalitis in a stem cell transplant recipient, this FAQ explains what the virus is, where it has spread, how the case was diagnosed, how the patient was likely infected and what clinicians should watch for.
ID Week Highlights Part 1
In this first IDWeek 2026 roundup, oral olorofim matched AmBisome in invasive aspergillosis, aztreonam-avibactam held activity as MBL-producing CRE rose, pritelivir cut hospitalizations in refractory HSV, and zelicapavir shortened RSV symptoms in high-risk adults.